Approximately 400,000 Americans are now taking the oral form of Wegovy, Novo Nordisk's weight-loss drug, just ten weeks after its January 5 launch, according to CNN [1]. The pill is the first oral GLP-1 receptor agonist approved for chronic weight management.

The FDA approved oral semaglutide 25 mg on December 22, 2025, and Novo Nordisk made it broadly available across the United States within two weeks [2]. Early real-world data from Truveta found that 36 percent of patients on the Wegovy pill were new to GLP-1 therapy entirely, suggesting the oral form is expanding the market rather than simply cannibalizing injectable prescriptions [3].

The pill eliminates the cold-chain storage requirements and needle anxiety that deterred some patients from the injectable version. In the OASIS-4 clinical trial, mean weight loss was 16.6 percent with adherence [4]. The once-daily tablet works through the same mechanism as injectable Wegovy, slowing gastric emptying and reducing appetite.

Novo Nordisk faces competition. Eli Lilly's oral GLP-1 candidate, orforglipron, is advancing toward anticipated approval in the second quarter of 2026 [5]. Meanwhile, the FDA recently approved a higher-dose injectable Wegovy at 7.2 mg, which demonstrated approximately 20.7 percent weight loss.

Analysts at UBS had projected that 400,000 first-quarter prescriptions would represent a strong benchmark for the oral launch. The pill's trajectory suggests that the obesity drug market is entering a new phase where injection reluctance is no longer a barrier to treatment.

-- Nora Whitfield, New York